The effects AZD8529 on cognition and negative symptoms in schizophrenics

Study identifier:D2285M00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Study to Access an Early Signal of Efficacy for Cognition and Negative Symptoms with AZD8529 in Patients with Schizophrenia

Medical condition

schizophrenia

Phase

Phase 1

Healthy volunteers

Study drug

AZD8529, Placebo to match AZD8529

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Nov 2009

Primary Completion Date: 01 Oct 2011

Study Completion Date: 01 Oct 2011

Study design

Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Oct 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Philadelphia, PA, United States

Arms	Assigned Interventions
Experimental: 1 80 mg AZD8529	Drug: AZD8529 2 capsules by mouth for 3 days
Placebo Comparator: 2 Placebo	Drug: Placebo to match AZD8529 2 capsules by mouth for 3 days

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Raquel Gur

Hospital of the University of Pennsylvania, Dept of Psychiatry, Neuropsychiatry Section